

ISSUER QUARTERLY REPORT

For the Period ended September 30, 2012

**VIRATECH CORP.
4719 Quail Lakes Drive #G319
Stockton, CA 95207
Telephone Number: (209) 377-3030**

ISSUER'S EQUITY SECURITIES

**Common Stock, authorized 2,000,000,000 shares
par value \$.0001 per share.
Preferred Stock, authorized 10,000,000 shares
par value \$.0001 per share.**

TRANSFER AGENT

**Standard Registrar and Transfer Co.
12528 S. 1840 E
Draper, UT 84020
Ph. (801) 571-8844**

SECURITIES COUNSEL

**Crawford Shaw
230 Park Avenue
10th Floor
New York, NY 10169
(917) 712-5544**

Item 1. Exact Name Of Issuer and Address of Principal Executive Offices.

The exact name of the issuer is VIRATECH CORP. The address of the issuer's principal executive offices is: 4719 Quail Lakes Drive #G319 Stockton, CA 95207. The telephone number of its executive offices is (209) 377-3030.

Item 2. Shares Outstanding.

As of September 30, 2012, there are 2,000,000,000 commons shares par value \$.0001 authorized and 20,000,000 preferred shares par value \$.0001 authorized. Currently, there are 724,980,550 shares of common stock outstanding and no shares of Preferred stock outstanding. As of that date, there were 19,726,558 shares in the public float, and approximately 155 shareholders of record.

Item 3. Interim Financial Statements.

The issuer's most recent financial statements as of September 30, 2012 are filed herewith.

Item 4. Management's Discussion and Analysis or Plan of Operation.

COMPANY OVERVIEW

Viratech was organized on March 21, 2000. Viratech is an open source biotechnology development company engaged in the business of researching and developing cancer treatment protocols through the use of open source web based research networks. Viratech's common stock is quoted on the pink sheets under the trading symbol, VIRA.

PLAN OF OPERATIONS - IN GENERAL

The Company holds the exclusive license to market proprietary and patented cancer diagnostic and treatment protocols, including the unified cancer theory, which is a multi-disciplinary oncological approach to identify the physiological mechanism of action for all cancers, the stage zero cancer protocol, an intellectual property pool consisting of best method practices of dealing with and managing individual cancer patients, and an early detection diagnostic system.

In order to facilitate the free flow of information, the Company entered into a non-exclusive licensing agreement with Extensions, Inc. to utilize the intellectual property of Extensions, Inc. to develop, manage and operate the web-based research and social network.

Recent Developments:

On July 16, 2011, Viratech Corp. approved the acquisition of Viratech, Inc., a corporation which held the exclusive license to market proprietary and patented cancer diagnostic treatment protocols. In connection with the acquisition, Viratech has changed its name to Viratech Corp. and effected a 1-100 reverse common stock split.

On August 22, 2011 Matt Heindel and Kevin Buckman, M.D. were appointed to the vacant positions of Board of Directors and subsequently Jeff Ritchie, former President and CEO of Imperia Entertainment, Inc. and Viratech Corp. resigned from both positions with the Company. Matt Heindel was appointed as Company President and CEO and Kevin Buckman, M.D. was appointed Vice President.

In this quarter, Kevin Buckman was appointed as Chief Executive Officer and Matt Heindel stayed on as President and director.

Matt Heindel, President/Director

Mr. Heindel spent nearly 30 years in the medical industry emphasizing the commercialization of Women's Health technologies. In 2005, Mr. Heindel was one of the early employees of NeoMatrix and was instrumental in the development of HALO, a breast cancer risk assessment tool which significantly improved the health of cancer patients while simultaneously minimizing the financial burden of the disease. Mr. Heindel's role at the start-up company ranged from selling the first units, creating the marketing launch plans to becoming the clinical expert for the company. Mr. Heindel was directly involved in guiding the company to revenue generation of over \$1M with over 200 devices in use including sales in several key international markets. In 2009, Mr. Heindel was key in recruiting Breast Surgeons who are key industry opinion leaders and commencing clinical data gathering necessary for cost reimbursement. In 2007 Mr. Heindel became the company's Chief Operating Officer responsible for sales, marketing, manufacturing, RA/QA and clinical programs.

Prior to NeoMatrix, Mr. Heindel was a minority owner and Vice President of Sales and Marketing for Prism Enterprises, a company whose primary products serviced the ob-gyn market. By rebuilding the company's sales and marketing division with key personnel upgrades and by making strategic acquisitions in 2002, the new owners took Prism Enterprises from a bankrupt company to an acquisition target of Cooper Surgical to whom it was sold for a significant return in 2003.

Mr. Heindel began his medical career with McGaw, Inc. an intravenous solutions and device company. During his 16 year career at McGaw, Inc. Mr. Heindel progressed from a sales representative to Vice President of International Sales when the company was acquired by B. Braun in 1998. While at McGaw, Inc. Mr. Heindel spent two years in the Middle East where his passion for International Markets emerged. Mr. Heindel has also served as Senior Vice-President of Worldwide Sales and Marketing for Quidel, a rapid diagnostics company focusing in the field of Women's Health.

Mr. Heindel brings a unique combination of skills and experience in domestic and international marketing of capital and disposable products within the medical field. His many years in the medical industry have afforded him a vast array of key distributors and relationships with domestic and international sales representatives as well as access to the medical industries key thought leaders.

Kevin Buckman, M.D., CEO/Director

Dr. Kevin Buckman MD FAAIM, MRO has been leading environmental projects since 1969 when he started his first national environmental project and an Ecology Club at his college campus. He grew up in Los Angeles and was concerned about pollution and its effect on our health. He completed his Medical School training at USC and continued his training there in Internal Medicine. He has become an expert in Environmental Medicine.

He has served as Medical Director in various hospitals and institutions for over 20 years. He has served as a member of the Executive Committee for six years at St. Dominic's Hospital in Manteca, California. He has written over ten patents for new medical and environmental technologies. From 1986 to 1997 there were more than 50 Physicians on his roster. He also served as Medical Director for Dameron Hospital EMS Liaison from 2002 to 2003. He became Board Certified in Emergency Medicine and a Fellow of the American Board of Emergency Medicine in 1990.

He has received numerous Certifications and Specialty Training in the field of Medicine. He is a Fellow in the American Association of Integrated Medicine, and a Board Certified Medical Review Officer. His other Specialties include: Internal Medicine, Forensic Medicine, Chinese Medicine and Acupuncture. He has over 25 years of hospital experience and has served on over 15 hospital committees.

He has presented research and given lectures at numerous hospitals and at International Medical Conferences and has traveled in 68 countries.

Dr. Buckman has studied in many fields of the environment and its effect on our health and the ecosystem as a whole. His focus is providing the best solutions for the concerns of climate changes.

Some of his positions include: Member of Sierra Club 1977 to 2003, Member of the Farm Bureau 2002 -2003, Member of the Northern California World Trade Center 2002-2003, Participant in World Trade Missions 1997 to present.

He has received Post Graduate Training at Stanford University School of Business, and attended seminars with the Securities Exchange Institute. He is the founder of the International Health Institute, a non-profit organization for a healthier environment. He has served as CEO for Lifeline BioTechnologies, Inc. a publically traded company, and he successfully advanced the medical technologies for the company as well as fund raising, and made International presentations. He has numerous Medical Publications and has written books about health.

During the last twenty years he has worked internationally to advance a number of medical technologies with a focus on the environmental causes of medical condition, the early detection of disease, preventive medicine, and non-harmful new methods of medical treatment. He is able to help the Company sustain continued growth of its principal source of income from solar and hybrid systems.

Item 5. Legal Proceedings.

None.

Item 6. Defaults upon senior securities.

None.

Item 7. Other Information.

The Company retired \$75,000 in past debt with the issuance of 75,000,000 shares of common stock. The Company needs to hire additional employees and managers but does not have the necessary cash to compensate the level of talent required to operate its business. Therefore, the Company has established a company Incentive Stock Option Plan and issued to the plan 150,000,000 shares of common stock.

Item 8. Exhibits.

See attached financial statements.

I, Kevin Buckman, certify that:

1. I have reviewed this quarterly report of Viratech Corp.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement fairly present in all material respects the financial condition, results of operation and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: November 28, 2012

/s/ Kevin Buckman

Kevin Buckman, Executive Officer

VIRATECH CORP.
BALANCE SHEETS
(Unaudited)
(Restated)

	Sept. 30, 2012
ASSETS	(Unaudited)
CURRENT ASSETS:	
Cash	\$ 53,258
TOTAL CURRENT ASSETS	\$ 53,258
Other Assets	
Intellectual Property	169,000
Interest in TV/film/scripts	\$ --
TOTAL ASSETS	\$ 222,258
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	
CURRENT LIABILITIES:	
Accounts Payable	\$ 300,000
Loans	0
TOTAL LIABILITIES	\$ 0
STOCKHOLDERS' EQUITY:	
Common stock, \$.0001 par value, Authorized shares: 2,000,000,000	
Issued and outstanding shares; 724,980,550	72,498
Preferred stock, \$.0001 par value, Issued and outstanding shares: 3,500,010	350
Paid-In Capital	786,455
Deficit accumulated during the development stage	(937,045)
Total Stockholders' Equity (Deficit)	(77,742)
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)	\$ \$222,258

VIRATECH CORP.**STATEMENT OF OPERATIONS**

For the period ended September 30, 2012 and 2011

(Unaudited)

(Restated)

	2012	2011
Income	\$ 0	\$ 0
Operating Expenses		
General and Administrative	60,942	0
Total Expenses	60,942	0
Net Income (Loss)	\$ (60,942)	\$ (0)

VIRATECH CORP.**STATEMENT OF CASH FLOWS**

For the Periods Ended Sept 30, 2012 and 2011

(Unaudited)

(Restated)

	2012	2011
CASH FLOWS FROM OPERATING ACTIVITIES		
Cash from Operating Activities	\$ 0	\$ 0
Net Loss	(0)	(0)
Net Cash Operating Activities	(0)	(0)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Stocks Issued for Cash and Services	114,200	0
Total Cash from Investing Activities	114,200	0
CASH FLOWS FROM FINANCING ACTIVITIES:		
Cash Provided By Financing	0	0
Net Cash Financing Activities	0	0
Increase (Decrease) in Cash	\$ 114,200	\$ (0)
Beginning Cash	\$ 114,200	\$ 0
Ending Cash	\$ 53,258	\$ 0

VIRATECH CORP.**STATEMENT OF STOCKHOLDER'S EQUITY**

For the Period Ended September 30, 2012

(Unaudited)

(Restated)

	Number of Shares Outstanding	Common Stock at Par Value	Paid In Capital	Deficit Accumulated During Development Stage
Beginning Balance (Post 1 for 100 common stock split)	715,715,550	\$ 71,572	\$ 673,181	\$ (876,103)
Shares issued for cash	9,265,000	926	113,274	
Additional Paid-In Capital				
Net loss – September 30, 2012				(60,942)
Balance – September 30, 2012	724,980,550	72,498	786,455	\$ (937,045)

Viratech Corp.
Notes to Financial Statements
September 30, 2012

NOTE 1 NATURE OF BUSINESS

Viratech Corp., formerly known as Imperia Entertainment, Soleil Film and Television, Inc., Ameridream Entertainment, Inc. and Mc Smoothie's, Inc. (the Company) was incorporated under the laws of the state of California as Acquisition Solutions on March 21, 2000. It runs a social networking website focused on open source biotech research.

Our new management has performed a thorough investigation of the assets and liabilities of the Company. As a result of this investigation, we have been unable to determine the appraised, depreciated value of the Company's film library. As a result of this uncertainty, we have written off the assets on our balance sheet.

In the event that any assets, liabilities, liens, judgments, warrants, options, or other claims against the Company arise, these will be recorded when discovered.

NOTE 2 SIGNIFICANT ACCOUNTING POLICIES

Basis. The Company uses the accrual method of accounting.

Cash and cash equivalents. The Company considers all short term, highly liquid investments that are readily convertible within three months to known amounts as cash equivalents. Currently, it has no cash equivalents.

Loss per share. Net loss per share is provided in accordance with Statement of Financial Accounting Standards No. 128 "Earnings Per Share". Basic loss per share reflects the amount of losses for the period available to each share of common stock outstanding during the reporting period, while giving effect to all dilutive potential common shares that were outstanding during the period, such as stock options and convertible securities.

Estimates. The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statement and accompanying notes. Actual results could differ from those estimates.

NOTE 3 INCOME TAXES

The Company has adopted the provision of SFAS No. 109 "Accounting for Income Taxes". It requires recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

NOTE 4 RELATED PARTY TRANSACTIONS

None

NOTE 5 FISCAL YEAR END

The Company's fiscal year end is December 31.

NOTE 6 RESTATEMENTS

As a result of writing off our film library for uncertainty, we have restated our financial statements.

NOTE 7 SUBSEQUENT EVENTS

None.